Vesynta

About Vesynta

Summary Vesynta is a HealthTech company based in London. Our decision support software helps clinicians to maximise therapeutic potential and the likelihood of success, by providing interpretable and personalised dosing insights at the point-of-care. Our mission is to ensure health equity for underserved patients, by making drug regimens safer, more efficacious and tailored to each individual. Our flagship projects include implementing precision dosing alongside a national paediatric oncology healthcare network, and predicting toxicity for a blockbuster immunotherapy with the Institute of Cancer Research. These are supported by $2m in non-dilutive funding and we are targeting market deployment in late 2025. Problem Drug dose selection currently relies upon convenient but coarse approaches that use patient weight or body-surface area as a guide. These approaches do not fully consider differences between how patient groups process their medication. This results in extreme variability in drug exposure, causing inequity in health outcomes by delivering limited therapeutic benefit or increasing the likelihood of toxicity. For example, over 1-in-4 cancer survivors suffer from treatment related side effects such as heart or nerve damage, highlighting a large quality of life issue. It is healthcare providers who have to pick up the bill of dose-related hospitalisations, costing nearly $500bn (US). It is also a problem for drug developers where early phase safety and efficacy issues lead to a 40% loss in drug candidates, costing $170bn per annum. Solution DosoLogic is a precision pharmacology software that improves the benefit/risk ratio when dosing critical therapies. The platform combines drug monitoring data with proprietary AI-models, for on-demand predictions of patient response, getting us to the right dose faster. Mission Ensuring health equity for underserved patients, by making drug regimens safer, more efficacious and tailored to each individual. Motivation & values We are driven each day to deliver health equity for patients (children, but also women and those with non-Caucasian ethnic heritages) who have been traditionally under-represented and poorly served by convenient but coarse dosing methodologies. By providing access to interpretable model- and data-informed personalised dosing recommendations; we ensure fewer toxic side effects, and significantly improved efficacy for life saving therapies, improving long-term quality of life for the patient.